However, in a small phase 2 trial comparing mosunetuzumab plus Pola-CHP (Pola-M-CHP) to Pola-R-CHP for first-line DLBCL, the complete response rates were similar (72.5% vs. 77.3%). Here, POLA1 is linked to diffuse large B-cell lymphoma.